Skip to main content
Clinical Trials/NCT06394817
NCT06394817
Recruiting
N/A

Beijing Disability Risk and Ageing Monitoring Study

Xuanwu Hospital, Beijing1 site in 1 country2,000 target enrollmentFebruary 20, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Age Problem
Sponsor
Xuanwu Hospital, Beijing
Enrollment
2000
Locations
1
Primary Endpoint
The conversion rate of normal to mild cognitive impairment
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.

Detailed Description

This is a community-based prospective cohort study. Individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. The study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. This work consists of three steps as following. First, we will build a community-based cohort and thus set up a database. Second, an intelligence model for disability risk assessment will be developed using the database. Third, a series of procedures will be established according to the risk assessment model.

Registry
clinicaltrials.gov
Start Date
February 20, 2023
End Date
May 2063
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 60 years or older
  • Lived in the community for more than 1 year
  • Signed the informed consent form

Exclusion Criteria

  • Cannot complete the survey

Outcomes

Primary Outcomes

The conversion rate of normal to mild cognitive impairment

Time Frame: An average of 1 to 2 years

Percentage of enrolled population that convert from normal to mild cognitive impairment

The biomarkers for normal, mild cognitive impairment, and dementia diagnosis

Time Frame: An average of 1 to 2 years

Humoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.

The prevalence and incidence of functional disability using a population-based survey

Time Frame: An average of 1 to 2 years

Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder(Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

The prevalence and incidence of dementia using a population-based survey

Time Frame: An average of 1 to 2 years

Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.

The conversion rate of mild cognitive impairment to dementia

Time Frame: An average of 1 to 2 years

Percentage of enrolled population that convert from mild cognitive impairment to dementia

The prevalence and incidence of mild cognitive impairment using a population-based survey

Time Frame: An average of 1 to 2 years

Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.

The genetic and environmental factors for mild cognitive impairment and dementia at genomic and expression levels

Time Frame: An average of 1 to 2 years

Discover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.

The prevalence and incidence of movement disorder using a population-based survey

Time Frame: An average of 1 to 2 years

Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

Study Sites (1)

Loading locations...

Similar Trials